Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - CHINA JO-JO DRUGSTORES, INC. | f8k111416_chinajojodrug.htm |
Exhibit 99.1
China Jo-Jo Drugstores Reports Fiscal 2017 Second Quarter Results
HANGZHOU, China, Nov. 14, 2016 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) today announced the financial results for its second fiscal quarter and six months ended September 30, 2016.
Second Quarter Highlights:
| ● | Revenue was $20.2 million compared to $22.6 million a year ago; | |
| ● | Gross profit increased 9.5% year-over-year to $4.4 million; | |
| ● | Gross margin increased 4% year-over-year to 21.6%, retail pharmacy gross margin increased 7.1% to 29.4% from a year ago; | |
| ● | GAAP net income was $97,870 or $0.01 per diluted share compared to net income of $151,175 or $0.01 per diluted share a year ago; | |
| ● | Adjusted net income was $746,504 or $0.04 per diluted share compared to adjusted net income of $34,689 or $0.00 per diluted share a year ago. |
Six Months Highlights:
| ● | Revenue was $41.1 million compared to $43.9 million a year ago; | |
| ● | Gross profit increased 5.8% year-over-year to $8.8 million; | |
| ● | Gross margin increased 2.5% year-over-year to 21.5%, retail pharmacy gross margin increased 5% to 29.0% from a year ago; | |
| ● | GAAP net income was $229,023 or $0.01 per diluted share compared to net income of $261,786 or $0.02 per diluted share a year ago; | |
| ● | Adjusted net income* was $1,500,504 or $0.08 per diluted share compared to adjusted net income* of $312,170 or $0.02 per diluted share a year ago. |
| * | Please see the note regarding the use of the non-GAAP financial measures and the table for the Reconciliation to non-GAAP Financial Measures at the end of this earnings release. |
Mr. Lei Liu, China Jo-Jo's Chairman and CEO, commented, "Our gross margin continued to expand, benefiting from more vendor rebates attributable to our focused marketing efforts in promoting brand-name pharmaceutical products, as we believe selling these products enhances our store popularity and customer loyalty. During the quarter, we achieved sales volume with certain brand pharmaceutical suppliers and received substantial rebates. In addition, now that the G20 summit is behind us, we have normalized our marketing activities and expect a rebound in retail sales in the third quarter."
Net revenues for the second quarter were $20.2 million compared to $22.6 million in the same quarter a year ago, a decrease of $2.4 million, or 10.7%. Lower revenue was mainly caused by the decline in online pharmacy business, which was partially offset by the increase in wholesale business.
Retail drugstores sales were $12.8 million compared to $13.1 million in the same quarter last year and $12.7 million in the first quarter of fiscal 2017. To improve same-store sales, the Company continued to optimize product mix, enable mobile payment, roll out in-pharmacy virtual doctor clinics, and work with reputable vendors to promote the sales of third-party brand products. The pharmacy store count increased to 62 as of September 30, 2016, compared to 59 stores a year ago.
Online pharmacy sales were $3.8 million compared to $6.6 million in the same quarter a year ago. The decrease was mainly due to (1) lower sales through third party e-commerce websites that resulted from the CFDA suspension of OTC drug sales on these platforms, and (2) the decline in transactions referred from Yikatong, the popular pharmacy and health insurance benefit card, in the Company's online pharmacy sales. To address these challenges, the Company is adding more non-medical health products such as nutritional supplements on the third party e-commerce platforms, while actively seeking alternative referral arrangements from other Pharmacy Benefit Management providers.
Gross profit increased by $376,000 or 9.5% year-over-year to $4.4 million. Gross margin increased from 17.6% to 21.6% due to higher retail profit margins. Retail gross margin increased primarily due to higher vendor rebates attributable to our marketing efforts in promoting brand-name products with large pharmaceutical suppliers, continuous efforts to renegotiate prices with our suppliers periodically, and selection of certain higher profit margin products.
Net income was $97,870 or $0.01 per diluted share compared to net income of $151,175 or $0.01 per diluted share in the same quarter a year ago.
Adjusted net income was $746,504 or $0.04 per diluted share compared to adjusted net income of $34,689 million or $0.00 per diluted share in the same quarter a year ago. Please see the note regarding the use of the non-GAAP financial measures and the table for the Reconciliation to non-GAAP Financial Measures at the end of this earnings release.
About China Jo-Jo Drugstores, Inc.
China Jo-Jo Drugstores, Inc. is a leading China-based pharmacy with retail, wholesale and online distribution of pharmaceutical and health care products through its online and retail pharmacies. As of September 30, 2016, the Company had 62 retail pharmacies in Zhejiang Province, China. The Company's wholesale subsidiary supplies its retail stores, and distributes drug and healthcare products to other drugstores and drug vendors. For more information, please visit: www.jiuzhou-drugstore.com (Chinese) and www.chinajojodrugstores.com (English). The Company routinely posts important information on its websites.
Forward Looking Statement
Statements in this press release regarding the Company that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements, including, but not limited to, financial guidance, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "estimate," "may," "will," "should," "project," "plan," "seek," "intend," "anticipate," the negatives thereof, or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. It is routine for the Company's internal projections and expectations to change as the quarter and year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which the Company bases its expectations may change. Although these expectations may change, the Company is under no obligation to inform you if they do. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of numerous factors, including the risks associated with the effect of changing economic conditions in the People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products. Readers are referred to the reports and documents filed from time to time by the Company with the Securities and Exchange Commission for a discussion of these and other important risk factors that could cause actual results to differ from those discussed in forward-looking statements. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
| 2 |
CHINA JO-JO DRUGSTORES, INC AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
| September 30, | March 31, | |||||||
| 2016 | 2016 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash | $ | 8,352,091 | $ | 6,671,873 | ||||
| Financial assets available for sale | 465,165 | |||||||
| Restricted cash | 6,949,808 | 13,747,990 | ||||||
| Notes receivable | 169,850 | 15,506 | ||||||
| Trade accounts receivable, net | 10,070,611 | 8,054,597 | ||||||
| Inventories | 13,767,234 | 10,802,691 | ||||||
| Other receivables, net | 1,738,864 | 1,376,468 | ||||||
| Advances to suppliers, net | 3,644,598 | 4,230,665 | ||||||
| Other current assets | 1,733,945 | 1,518,048 | ||||||
| Total current assets | 46,427,001 | 46,883,003 | ||||||
| PROPERTY AND EQUIPMENT, net | 4,986,110 | 5,543,076 | ||||||
| OTHER ASSETS | ||||||||
| Long-term investment | 179,904 | 108,539 | ||||||
| Farmland assets | 1,546,112 | 1,562,205 | ||||||
| Long term deposits | 2,370,850 | 2,452,056 | ||||||
| Other noncurrent assets | 2,859,998 | 2,595,129 | ||||||
| Intangible assets, net | 2,818,340 | 2,928,779 | ||||||
| Total other assets | 9,775,204 | 9,646,708 | ||||||
| Total assets | $ | 61,188,315 | $ | 62,072,787 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Short-term loan payable | $ | 29,984 | $ | 31,011 | ||||
| Accounts payable, trade | 21,208,208 | 16,667,396 | ||||||
| Notes payable | 11,674,166 | 17,595,634 | ||||||
| Other payable | 1,756,456 | 1,917,821 | ||||||
| Other payable - related parties | 2,271,790 | 2,199,775 | ||||||
| Customer deposits | 2,678,671 | 2,610,151 | ||||||
| Taxes payable | 164,904 | 483,770 | ||||||
| Accrued liabilities | 592,881 | 615,056 | ||||||
| Total current liabilities | 40,377,060 | 42,120,614 | ||||||
| Warrant liability | 578,156 | 636,301 | ||||||
| Total liabilities | 40,955,216 | 42,756,915 | ||||||
| STOCKHOLDERS' EQUITY | ||||||||
| Common stock; $0.001 par value; 250,000,000 shares authorized; 19,425,678 and 17,735,504 shares issued and outstanding as of September 30, 2016 and March 31, 2016 | 19,426 | 17,736 | ||||||
| Additional paid-in capital | 23,416,150 | 22,088,267 | ||||||
| Statutory reserves | 1,309,109 | 1,309,109 | ||||||
| Accumulated deficit | (7,396,547 | ) | (6,957,053 | ) | ||||
| Accumulated other comprehensive income | 2,884,961 | 2,857,813 | ||||||
| Total stockholders' equity | 20,233,099 | 19,315,872 | ||||||
| Total liabilities and stockholders' equity | $ | 61,188,316 | $ | 62,072,787 | ||||
| 3 |
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
| For the three months ended September 30, | For the six months ended September 30, | |||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||
| REVENUES, NET | $ | 20,160,835 | $ | 22,577,626 | $ | 41,096,750 | $ | 43,888,918 | ||||||||
| COST OF GOODS SOLD | 15,807,828 | 18,600,619 | 32,261,939 | 35,536,228 | ||||||||||||
| GROSS PROFIT | 4,353,007 | 3,977,007 | 8,834,811 | 8,352,690 | ||||||||||||
| SELLING EXPENSES | 3,023,322 | 3,418,755 | 5,706,043 | 6,515,124 | ||||||||||||
| GENERAL AND ADMINISTRATIVE EXPENSES | 1,382,650 | 839,842 | 3,301,132 | 1,760,072 | ||||||||||||
| TOTAL OPERATING EXPENSES | 4,405,972 | 4,258,597 | 9,007,175 | 8,275,196 | ||||||||||||
| (LOSS) INCOME FROM OPERATIONS | (52,965 | ) | (281,590 | ) | (172,364 | ) | 77,494 | |||||||||
| INTEREST INCOME | 61,035 | 115,740 | 285,457 | 190,737 | ||||||||||||
| INTEREST EXPENSE | (430 | ) | 5,925 | (869 | ) | (154,006 | ) | |||||||||
| OTHER INCOME, NET | 17,425 | 145,597 | 104,624 | 107,082 | ||||||||||||
| CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES | 90,289 | 200,903 | 58,093 | 158,066 | ||||||||||||
| INCOME BEFORE INCOME TAXES | 115,354 | 113,113 | 274,941 | 305,911 | ||||||||||||
| PROVISION FOR INCOME TAXES (BENEFIT) | 17,484 | (38,062 | ) | 49,518 | 44,125 | |||||||||||
| NET INCOME | 97,870 | 151,175 | 229,023 | 261,786 | ||||||||||||
| OTHER COMPREHENSIVE (LOSS) INCOME | ||||||||||||||||
| Foreign currency translation adjustments | (87,721 | ) | (860,853 | ) | 27,148 | (774,553 | ) | |||||||||
| COMPREHENSIVE (LOSS) INCOME | $ | (10,149 | ) | $ | (709,678 | ) | $ | 256.171 | $ | (512,767 | ) | |||||
| WEIGHTED AVERAGE NUMBER OF SHARES: | ||||||||||||||||
| Basic | 19,375,773 | 16,537,461 | 18,239,065 | 16,096,406 | ||||||||||||
| Diluted | 19,375,773 | 16,588,559 | 18,239,065 | 16,147,505 | ||||||||||||
| EARNINGS PER SHARES: | ||||||||||||||||
| Basic | $ | 0.01 | $ | 0.01 | $ | 0.01 | $ | 0.02 | ||||||||
| Diluted | $ | 0.01 | $ | 0.01 | $ | 0.01 | $ | 0.02 | ||||||||
| 4 |
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| Six months ended September 30, | ||||||||
| 2016 | 2015 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net income | $ | 229,023 | 261,786 | |||||
| Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities: | ||||||||
| Depreciation and amortization | 466,570 | 763,839 | ||||||
| Stock-based compensation | 1,329,574 | 208,450 | ||||||
| Bad debt provision | (177,274 | ) | (1,540,695 | ) | ||||
| Change in fair value of purchase option derivative liability | (58,145 | ) | (158,066 | ) | ||||
| Change in operating assets: | ||||||||
| Accounts receivable, trade | (2,190,470 | ) | 716,075 | |||||
| Notes receivable | (156,527 | ) | 98,698 | |||||
| Inventories | (3,358,110 | ) | (1,371,177 | ) | ||||
| Other receivables | (176,334 | ) | (556,942 | ) | ||||
| Advances to suppliers | 275,098 | 748,185 | ||||||
| Other current assets | (269,040 | ) | 615,329 | |||||
| Other noncurrent assets | (354,594 | ) | - | |||||
| Change in operating liabilities: | ||||||||
| Accounts payable, trade | 5,147,686 | 2,924,110 | ||||||
| Other payables and accrued liabilities | (102,920 | ) | 1,133,850 | |||||
| Customer deposits | 156,632 | (2,460,559 | ) | |||||
| Taxes payable | (306,109 | ) | 116,924 | |||||
| Net cash provided by operating activities | 455,060 | 1,499,807 | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchase of equipment | (49,298 | ) | (106,200 | ) | ||||
| Decrease in Financial assets available for sale | 454,608 | 1,293,600 | ||||||
| Investment in a joint venture | (75,768 | ) | (113,190 | ) | ||||
| Additions to leasehold improvements | (26,262 | ) | - | |||||
| Net cash provided by (used in) investing activities | 303,280 | 1,074,210 | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from short-term bank loan | - | 23,580 | ||||||
| Repayment of short-term bank loan | - | (31,665 | ) | |||||
| Change in restricted cash | 6,411,257 | (4,279,182 | ) | |||||
| Repayments of notes payable | (17,196,298 | ) | (15,589,077 | ) | ||||
| Proceeds from notes payable | 11,800,003 | 17,407,506 | ||||||
| Proceeds from other payables-related parties | 95,088 | 69,977 | ||||||
| Proceeds from equity financing | - | 2,699,500 | ||||||
| Net cash provided by financing activities | 1,110,050 | 300,639 | ||||||
| EFFECT OF EXCHANGE RATE ON CASH | (188,172 | ) | (188,652 | ) | ||||
| INCREASE IN CASH | 1,680,218 | 2,686,004 | ||||||
| CASH, beginning of period | 6,671,873 | 4,023,581 | ||||||
| CASH, end of period | $ | 8,352,091 | $ | 6,709,585 | ||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||
| Cash paid for interest | $ | 869 | $ | 158,415 | ||||
| Cash paid for income taxes | $ | 42,437 | $ | 35,943 | ||||
| Non-cash financing activities: | ||||||||
| Issuance of stock purchase options to an investor | - | 1,231,067 | ||||||
| Issuance of stock purchase options to an investment bank | - | $ | 147,728 | |||||
| 5 |
Use of non-GAAP financial measures
To supplement China Jo-Jo's consolidated financial results presented in accordance with GAAP, China Jo-Jo uses the following measures defined as non-GAAP financial measures by the SEC: net income (loss) excluding share-based compensation expenses and change in fair value of derivative liabilities, and diluted net income (loss) per share excluding share-based compensation expenses and change in the fair value of derivatives liabilities. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.
China Jo-Jo believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity by excluding share-based compensation expenses and change in fair value of derivative liabilities that may not be indicative of its operating performance from a cash perspective. China Jo-Jo believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to China Jo-Jo's historical performance and liquidity. China Jo-Jo computes its non-GAAP financial measures using the same consistent method from quarter to quarter. China Jo-Jo believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision-making. A limitation of using these non-GAAP measures is that they exclude share-based compensation and change in fair value of derivative liabilities charge that has been and will continue to be for the foreseeable future a significant recurring expense in our business. Management compensates for these limitations by providing specific information regarding the GAAP amounts excluded from each non-GAAP measure. The table under the heading Reconciliation to non-GAAP Financial Measures in the beginning of the release has more details on the reconciliations between GAAP financial measures that are most directly comparable to non-GAAP financial measures.
Reconciliation to non-GAAP Financial Measures
| Three Months Ended September 30, | Six Months Ended September 30, | |||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||
| Net income | $ | 97,870 | $ | 151,175 | $ | 229,023 | $ | 261,786 | ||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Share based compensation expense | 738,923 | 84,417 | 1,329,574 | 208,450 | ||||||||||||
| Change in fair value of derivative liabilities | (90,341 | ) | (200,903 | ) | (58,145 | ) | (158,066 | ) | ||||||||
| Adjusted net income | 746,452 | 34,689 | 1,500,452 | 312,170 | ||||||||||||
| Adjusted net income per share - diluted | 0.04 | 0.00 | 0.08 | 0.02 | ||||||||||||
Investor
Relations Contact:
Steve Liu
steve.liu@jojodrugstores.com
CONTACT: Steve Liu, +86-571-88219579, steve.liu@jojodrugstores.com
6